Primary sclerosing cholangitis - What is the difference between East and West?

World Journal of Gastroenterology

Volumn 14, Issue 25, 2008, Pages 3974-3981

  Shorbagi, Ali ^a   Bayraktar, Yusuf ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Chola ngiocellular carcinoma; Endoscopic retrograde cholangiopancreatography; Magnetic resonance cholangiopancreatography; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

AUTOANTIBODY; COLCHICINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENICILLAMINE; PENTOXIFYLLINE; PLACEBO; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

AGE; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BONE DISEASE; CHOLELITHIASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMON BILE DUCT STONE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL RADIOGRAPHY; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; IMMUNOGENETICS; JAPANESE; LABORATORY TEST; LIVER DISEASE; LIVER TRANSPLANTATION; METABOLIC DISORDER; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; SYMPTOMATOLOGY; TURKEY (REPUBLIC); ADULT; ASIAN; CAUCASIAN; COMPARATIVE STUDY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ETHNOLOGY; EUROPE; FEMALE; JAPAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; JAPAN; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 53449098934     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3974     Document Type: Article

References (62)

1. Batres LA, Russo P, Mathews M, Piccoli DA, Chuang E, Ruchelli E. Primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol 2005; 8: 568-576
2. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan-analysis of 192 cases. J Gastroenterol 1997; 32: 134-137
3. Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004; 29: 153-159
4. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, Reitsma JB, Heisterkamp SH, Tytgat GN. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562-566
5. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615
6. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007; 102: 107-114
7. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TF, Fisher LD, Beaver SJ, LaRusso NF. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-436
8. Bayraktar Y, Arslan S, Saglam F, Uzunalimoglu B, Kayhan B. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients? Hepatogastroenterology 1998; 45: 2064-2072
9. Osmanoglu N, Tekin F, Ozutemiz O, Ersoz G, Tekesin O. The prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis. Turk J Gastroenterol 2005; 16: 240-241
10. Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B. Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey. J Clin Gastroenterol 2001; 33: 299-301
11. Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 1065-1072
12. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 150-157
13. Schrumpf E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982; 17: 187-191
14. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983; 24: 38-41
15. Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, Eddleston AL, Williams R. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 390-395
16. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990; 322: 1842-1844
17. Grunnet N, Rasmussen HH, Tage-Jensen U, Norby Rasmussen S. Association of primary sclerosing cholangitis with HLA-DRw52a? Tissue Antigens 1991; 38: 133-136
18. Wiencke K, Spurkland A, Schrumpf E, Boberg KM. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 2001; 34: 625-630
19. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002; 35: 555-564
20. Neri TM, Cavestro GM, Seghini P, Zanelli PF, Zanetti A, Savi M, Podda M, Zuin M, Colombo M, Floreani A, Rosina F, Bianchi Porro G, Strazzabosco M, Okolicsanyi L. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis 2003; 35: 571-576
21. Yang X, Cullen SN, Li JH, Chapman RW, Jewell DP. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004; 40: 375-379
22. Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 629-642
23. Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006; 5: 449-457
24. Kita H, Mackay IR, Van De Water J, Gershwin ME. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001; 120: 1485-1501
25. Delbet P. Retrecissement du choledoque cholecystoduodenostomie. Bull Mem Soc Chir Paris 1924; 50: 3
26. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149: 39-44
27. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310:899-903
28. Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4: 514-520
29. Moff SL, Kamel IR, Eustace J, Lawler LP, Kantsevoy S, Kalloo AN, Thuluvath PJ. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64: 219-223
30. Johnson GK, Saeian K, Geenen JE. Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation. Curr Gastroenterol Rep 2006; 8: 147-155
31. Johnson GK, Geenen JE, Venu RP, Hogan WJ. Endoscopic treatment of biliary duct strictures in sclerosing cholangitis: follow-up assessment of a new therapeutic approach. Gastrointest Endosc 1987; 33: 9-12
32. Johnson GK, Geenen JE, Venu RP, Schmalz MJ, Hogan WJ. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991; 37: 38-43
33. Ponsloen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 2403-2407
34. Kaya M, de Groen PC, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, Haddock MG, Lindor KD. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol 2001; 96: 1164-1169
35. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31: 7-11
36. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667
37. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006; 26: 42-51
38. Baron TH, Harewood GC, Rumalla A, Pochron NL, Stadheim LM, Gores GJ, Therneau TM, De Groen PC, Sebo TJ, Salomao DR, Kipp BR. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004; 2: 214-219
39. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, Sebo TJ, Therneau TM, Gores GJ, de Groen PC, Baron TH, Levy MJ, Halling KC, Roberts LR. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-1681
40. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29: 1003-1006
41. Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20: 215-219
42. Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RA, LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257-261
43. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000; 33: 878-882
44. Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, Monegal A, Martínez de Osaba MJ, Roca M, Peris P, Rodés J. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2268-2274
45. Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006; 12: 3487-3495
46. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695
47. Okolicsanyi L, Groppo M, Floreani A, Morselli-Labate AM, Rusticali AG, Battocchia A, Colombo M, Galatola G, Gasbarrini G, Podda M, Ricci G, Rosina F, Zuin M. Treatment of primary sclerosing cholangitis with lowdose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis 2003; 35: 325-331
48. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman Q. Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472
49. Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2003; CD003626
50. Sekhon JS, Chung RT, Epstein M, Kaplan MM. Steroid-responsive (autoimmune?) sclerosing cholangitis. Dig Dis Sci 2005; 50: 1839-1843
51. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991; 86: 57-61
52. van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR. Budesonide or prednisone in combination with ursodeoxycholic acid in Primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000; 95: 2015-2022
53. Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J Hepatol 1986; 3: 118-122
54. Tiandra K, Le T, Swain MG. Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis. Gut 2003; 52: 1363-1370
55. Lee YM, Kaplan MM, Gheorghe L. [Guidelines for the diagnosis and therapy of primary sclerosing cholangitis. Guidelines of the American College of Gastroenterology 2002] Rom J Gastroenterol 2002; 11: 346-350
56. Kaplan MM. Toward better treatment of primary sclerosing cholangitis. N Engl J Med 1997; 336: 719-721
57. Brandsaeter B, Isoniemi H, Broomé U, Olausson M, Backman L, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Höckerstedt K, Mäkisalo H, Kirkegaard P, Friman S, Bjøro K. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815-822
58. Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 21: 933-948
59. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313
60. Ricci P, Therneau TM, Malinchoc M, Benson JT, Petz JL, Klintmalm GB, Crippin JS, Wiesner RH, Steers JL, Rakela J, Starzl TE, Dickson ER. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology 1997; 25: 672-677
61. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangids, and autoimmune hepatitis. Liver Transpl Surg 1995; 1: 109-115
62. Neuberger J, Gunson B, Komolmit P, Davies MH, Christensen E. Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model. Hepatology 1999; 29: 1375-1379